Lung Cancer

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.

Ramaswamy Govindan, MD, discusses the rapid therapeutic changes in NSCLC and the sequencing questions physicians are currently asking.

Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard care with platinum-based chemotherapy and radiotherapy.

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).

Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

The FDA has granted an accelerated approval to pembrolizumab for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in non-small cell lung cancer and what researchers are poised to do next in the field.

Jeffrey P. Ward, MD, PhD, discusses the questions researchers still face about targeting the immune system and exactly what role T-cell receptor therapy could play in the treatment of patients with non-small cell lung cancer.

Siddhartha Devarakonda, MD, discusses the importance of testing for molecular markers in NSCLC, rare mutations, and what work lies ahead for the field of lung cancer.

Jonathan Riess, MD, shares his insight on the game-changing efficacy of osimertinib in non-small cell lung cancer and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the EGFR-mutant population.

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Mary Jo Fidler, MD, discusses aiming to improve platinum-based doublet therapy in NSCLC, as well as the role of chemotherapy for non-driver adenocarcinoma in the future.

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

The FDA has granted brigatinib (Alunbrig) an accelerated approval as a treatment for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.